EGFR and non-small cell lung carcinoma: NSCLC patients with acquired resistance to EGFR-TKIs (tyrosine kinase inhibitors) could achieve superior efficacy of anti-PD-1/PD-L1 blockers, as specific T-cell responses could be achieved with high-value neoantigens generated from EGFR driver mutations [119].